We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
NBIX is set to report Q4 results on Feb. 11, with revenue growth expected from higher product sales.
NBIX's revenues are likely to be driven mainly by Ingrezza sales, supported by Crenessity growth & royalties.
NBIX expenses are expected to rise as it invests in late-stage pipeline studies and the Crenessity launch.
Neurocrine Biosciences (NBIX - Free Report) is slated to report its fourth-quarter 2025 results on Feb. 11, after market close. We expect investors to focus on the sales performance of NBIX’s marketed drugs and other pipeline updates when it reports fourth-quarter 2025 results.
The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $784.42 million. The consensus mark for Neurocrine Biosciences’ earnings per share is pinned at $2.27.
Let's see how things might have shaped up for NBIX in the soon-to-be-reported quarter.
Factors to Consider Regarding NBIX’s Q4 Earnings
Neurocrine Biosciences derives the bulk of its revenues from Ingrezza (valbenazine), its flagship FDA-approved therapy for tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Since its U.S. launch in 2017, Ingrezza has become the company’s primary growth engine, accounting for substantially all net product sales.
Neurocrine Biosciences’ second marketed product, Crenessity (crinecerfont), was launched in the United States in 2024 for the treatment of classic congenital adrenal hyperplasia. Both marketed drugs have posted sequential growth in all three quarters of 2025. This trend is expected to have continued in the fourth quarter as well.
Neurocrine Biosciences earns royalty income from partners, including Mitsubishi Tanabe Pharma Corporation on international sales of Dysval/Remleas (valbenazine), approved for TD, and AbbVie on U.S. sales of elagolix-based products for endometriosis and uterine fibroids, adding to the top line.
Total revenues are expected to have jumped year over year in the fourth quarter of 2025, driven by the increased sales of Neurocrine Biosciences’ marketed portfolio as well as on account of higher collaboration revenues from its partners.
Neurocrine Biosciences shares have gained 7.3% in the past six months against the industry’s 0.3% decline.
Image Source: Zacks Investment Research
Investors will also likely be interested in updates regarding NBIX’s late-stage pipeline on the fourth-quarter earnings call. The company is currently evaluating its lead pipeline candidate, direclidine (NBI-1117568), a potential first-in-class, orally active, highly selective investigational M4 agonist, in two phase III studies for schizophrenia. Another investigational candidate, osavampator (NBI-1065845), a potential first-in-class AMPA PAM, is currently being evaluated in a separate phase III study for major depressive disorder.
Beyond its late-stage pipeline, Neurocrine Biosciences is advancing a diversified early- to mid-stage pipeline programs spanning multiple therapeutic modalities, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies, targeting under-addressed neuropsychiatric, neurological, and neuroendocrine disorders.
Research and Development expenses in the fourth quarter of 2025 are expected to have increased due to increased investments in clinical and pre-clinical activities.
Fourth-quarter selling, general, and administrative expenses are expected to have risen primarily due to incremental investments supporting the launch of Crenessity.
NBIX’s Earnings Surprise History
Neurocrine Biosciences has a mixed earnings surprise history so far. Earnings surpassed estimates in two of the trailing four quarters, while missing the mark on the other two occasions, delivering an average negative surprise of 20.01%. In the last reported quarter, the company delivered an earnings surprise of 29.11%.
Earnings Whispers for NBIX
Our proven model does not conclusively predict an earnings beat for Neurocrine Biosciences this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Neurocrine Biosciences has an Earnings ESP of +1.90% as the Most Accurate Estimate of $2.32 per share exceeds the Zacks Consensus Estimate of $2.27.
Zacks Rank: Neurocrine Biosciences currently carries a Zacks Rank #4 (Sell).
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +80.95% and sports a Zacks Rank #1 at present.
Shares of CSTL have rallied 77% in the past six months. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%.
Moderna (MRNA - Free Report) has an Earnings ESP of +3.16% and a Zacks Rank #3 at present.
Shares of MRNA have risen 60.1% in the past six months. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%. Moderna is scheduled to report fourth-quarter results on Feb. 13.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +15.85% and a Zacks Rank #3 at present.
Shares of CRSP have lost 10.9% in the past six months. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. CRISPR Therapeutics delivered an average surprise of 15.23%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
Key Takeaways
Neurocrine Biosciences (NBIX - Free Report) is slated to report its fourth-quarter 2025 results on Feb. 11, after market close. We expect investors to focus on the sales performance of NBIX’s marketed drugs and other pipeline updates when it reports fourth-quarter 2025 results.
The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $784.42 million. The consensus mark for Neurocrine Biosciences’ earnings per share is pinned at $2.27.
Let's see how things might have shaped up for NBIX in the soon-to-be-reported quarter.
Factors to Consider Regarding NBIX’s Q4 Earnings
Neurocrine Biosciences derives the bulk of its revenues from Ingrezza (valbenazine), its flagship FDA-approved therapy for tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Since its U.S. launch in 2017, Ingrezza has become the company’s primary growth engine, accounting for substantially all net product sales.
Neurocrine Biosciences’ second marketed product, Crenessity (crinecerfont), was launched in the United States in 2024 for the treatment of classic congenital adrenal hyperplasia. Both marketed drugs have posted sequential growth in all three quarters of 2025. This trend is expected to have continued in the fourth quarter as well.
Neurocrine Biosciences earns royalty income from partners, including Mitsubishi Tanabe Pharma Corporation on international sales of Dysval/Remleas (valbenazine), approved for TD, and AbbVie on U.S. sales of elagolix-based products for endometriosis and uterine fibroids, adding to the top line.
Total revenues are expected to have jumped year over year in the fourth quarter of 2025, driven by the increased sales of Neurocrine Biosciences’ marketed portfolio as well as on account of higher collaboration revenues from its partners.
Neurocrine Biosciences shares have gained 7.3% in the past six months against the industry’s 0.3% decline.
Image Source: Zacks Investment Research
Investors will also likely be interested in updates regarding NBIX’s late-stage pipeline on the fourth-quarter earnings call. The company is currently evaluating its lead pipeline candidate, direclidine (NBI-1117568), a potential first-in-class, orally active, highly selective investigational M4 agonist, in two phase III studies for schizophrenia. Another investigational candidate, osavampator (NBI-1065845), a potential first-in-class AMPA PAM, is currently being evaluated in a separate phase III study for major depressive disorder.
Beyond its late-stage pipeline, Neurocrine Biosciences is advancing a diversified early- to mid-stage pipeline programs spanning multiple therapeutic modalities, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies, targeting under-addressed neuropsychiatric, neurological, and neuroendocrine disorders.
Research and Development expenses in the fourth quarter of 2025 are expected to have increased due to increased investments in clinical and pre-clinical activities.
Fourth-quarter selling, general, and administrative expenses are expected to have risen primarily due to incremental investments supporting the launch of Crenessity.
NBIX’s Earnings Surprise History
Neurocrine Biosciences has a mixed earnings surprise history so far. Earnings surpassed estimates in two of the trailing four quarters, while missing the mark on the other two occasions, delivering an average negative surprise of 20.01%. In the last reported quarter, the company delivered an earnings surprise of 29.11%.
Earnings Whispers for NBIX
Our proven model does not conclusively predict an earnings beat for Neurocrine Biosciences this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Neurocrine Biosciences has an Earnings ESP of +1.90% as the Most Accurate Estimate of $2.32 per share exceeds the Zacks Consensus Estimate of $2.27.
Zacks Rank: Neurocrine Biosciences currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Neurocrine Biosciences, Inc. Price, Consensus and EPS Surprise
Neurocrine Biosciences, Inc. price-consensus-eps-surprise-chart | Neurocrine Biosciences, Inc. Quote
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +80.95% and sports a Zacks Rank #1 at present.
Shares of CSTL have rallied 77% in the past six months. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. Castle Biosciences delivered an average surprise of 66.11%.
Moderna (MRNA - Free Report) has an Earnings ESP of +3.16% and a Zacks Rank #3 at present.
Shares of MRNA have risen 60.1% in the past six months. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.45%. Moderna is scheduled to report fourth-quarter results on Feb. 13.
CRISPR Therapeutics (CRSP - Free Report) has an Earnings ESP of +15.85% and a Zacks Rank #3 at present.
Shares of CRSP have lost 10.9% in the past six months. The company’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. CRISPR Therapeutics delivered an average surprise of 15.23%.